Pharmacogenomics

Pharmacogenomics

药物基因组学

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Pharmacogenomics》是由Future Medicine Ltd.出版社于2000年创办的英文国际期刊(ISSN: 1462-2416,E-ISSN: 1744-8042),该期刊长期致力于药学领域的创新研究,主要研究方向为医学-药学。作为SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0.1019...%),以发表药学领域等方向的原创性研究为核心(研究类文章占比80.00%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在75篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Pharmacogenomics审稿周期约为 偏慢,4-8周 。该刊近年未被列入国际预警名单,年发文量约75篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 75 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
PHARMACOLOGY & PHARMACY 药学
4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
PHARMACOLOGY & PHARMACY 药学
4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q3 231 / 354

34.9%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q3 257 / 354

27.54%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:3.4 SJR:0.439 SNIP:0.395
学科类别 分区 排名 百分位
大类:Pharmacology, Toxicology and Pharmaceutics 小类:Pharmacology Q3 194 / 313

38%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Genetics Q3 236 / 347

32%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Molecular Medicine Q3 129 / 178

27%

期刊发文

  • SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients

    Author: Zhong, Jianxun; Yang, Kun; Zhang, Mi; Wu, Jianhua; Liu, Liang

    Journal: PHARMACOGENOMICS. 2023; Vol. 24, Issue 2, pp. 83-91. DOI: 10.2217/pgs-2022-0101

  • Pharmacogenomics of oxcarbazepine in the treatment of epilepsy

    Author: Yuan, Yujie; Zhang, Shuang; Yuan, Yangyang; Yan, Xinjing; Zhang, Linlin; Ran, Yun Wei

    Journal: PHARMACOGENOMICS. 2023; Vol. , Issue , pp. -. DOI: 10.2217/pgs-2022-0177

  • Application of next-generation sequencing in diffuse large B-cell lymphoma

    Author: Wang, Yudi; Jia, Suzhen; Cao, Xiubo; Ge, Shengchen; Yu, Kang; Chen, Yi

    Journal: PHARMACOGENOMICS. 2023; Vol. 24, Issue 1, pp. 59-68. DOI: 10.2217/pgs-2022-0140

  • A single-tube multiplex real-time PCR for HLA-B*38:02 genotype by detecting highly specific SNPs

    Author: Wang, Fei; Li, Wenqi; Wang, Xuan; Luo, Xiang; Dai, Penggao

    Journal: PHARMACOGENOMICS. 2023; Vol. 24, Issue 1, pp. 5-14. DOI: 10.2217/pgs-2022-0132

  • Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients

    Author: Zheng, Xiao-Xiao; You, Yu-Xin; Zhao, Lin-Lin; Du, Yan; Xu, Sheng-Qiu; Tang, Dao-Quan

    Journal: PHARMACOGENOMICS. 2023; Vol. , Issue , pp. -. DOI: 10.2217/pgs-2022-0156

  • Association of CYP2C19, CYP3A4 and ABCC2 polymorphisms and voriconazole plasma concentrations in Uygur pediatric patients

    Author: Zhao, Ting; Shen, Hao; Zhang, Hui-lan; Feng, Jie; Liu, Si-ming; Wang, Ting-ting; Li, Hong-jian; Yu, Lu-hai

    Journal: PHARMACOGENOMICS. 2023; Vol. , Issue , pp. -. DOI: 10.2217/pgs-2022-0159

  • DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells

    Author: Liu, Jianhong; Yang, Xu; Gao, Shasha; Wen, Minya; Yu, Qiong

    Journal: PHARMACOGENOMICS. 2023; Vol. , Issue , pp. -. DOI: 10.2217/pgs-2022-0121

  • Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention

    Author: Jin, Hui; Song, Jinfei; Shen, Xiaoying; Liang, Qing; Sun, Guangchun; Yu, Yan

    Journal: PHARMACOGENOMICS. 2023; Vol. 24, Issue 4, pp. 227-237. DOI: 10.2217/pgs-2022-0167